Cyclooxygenases and the cardiovascular system.

Mitchell, Jane A, Kirkby, Nicholas S, Ahmetaj-Shala, Blerina, Armstrong, Paul C, Crescente, Marilena ORCID: https://orcid.org/0000-0003-3164-512X, Ferreira, Plinio, Lopes Pires, Maria Elisa, Vaja, Ricky and Warner, Timothy D (2021) Cyclooxygenases and the cardiovascular system. Pharmacology and Therapeutics, 217. p. 107624. ISSN 0163-7258

Preview

Accepted Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (1MB) | Preview

Abstract

Cyclooxygenase (COX)-1 and COX-2 are centrally important enzymes within the cardiovascular system with a range of diverse, sometimes opposing, functions. Through the production of thromboxane, COX in platelets is a pro-thrombotic enzyme. By contrast, through the production of prostacyclin, COX in endothelial cells is antithrombotic and in the kidney regulates renal function and blood pressure. Drug inhibition of COX within the cardiovascular system is important for both therapeutic intervention with low dose aspirin and for the manifestation of side effects caused by nonsteroidal anti-inflammatory drugs. This review focuses on the role that COX enzymes and drugs that act on COX pathways have within the cardiovascular system and provides an in-depth resource covering COX biology and pharmacology. The review goes on to consider the role of COX in both discrete cardiovascular locations and in associated organs that contribute to cardiovascular health. We discuss the importance of, and strategies to manipulate the thromboxane: prostacyclin balance. Finally within this review the authors discuss testable COX-2-hypotheses intended to stimulate debate and facilitate future research and therapeutic opportunities within the field.